Total debt of about $1.1B against equity of $296.4M yields a debt-to-equity ratio of 3.67 and a current ratio that fell to 1.01, which suggests leverage remains structurally high with a thin liquidity buffer.
Collegium Pharmaceutical, Inc. (COLL) balance sheet — 13-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Total Current Assets | 611.75M | 691.41M | 482.26M | 537.6M | 419.99M | 315.54M | 277.89M | 255.72M | 237.51M | 133.48M | 158.57M | 96.88M | 4.5M | 8.26M |
| Cash & Short-Term Investments | 144.8M | 406.53M | 162.76M | 310.55M | 173.69M | 186.43M | 174.12M | 170.02M | 146.63M | 118.7M | 153.22M | 95.7M | 1.63M | 7.55M |
| Cash Only | 144.8M | 251.1M | 70.56M | 238.95M | 173.69M | 186.43M | 174.12M | 170.02M | 146.63M | 118.7M | 153.22M | 95.7M | 1.63M | 7.55M |
| Short-Term Investments | 0 | 155.43M | 92.2M | 71.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 310.79M | 211.33M | 228.54M | 179.53M | 183.12M | 105.84M | 83.32M | 72.95M | 77.95M | 9.97M | 2.13M | 0 | 0 | 0 |
| Days Sales Outstanding | 115.96 | 98.82 | 132.1 | 115.61 | 144.07 | 139.54 | 98.1 | 89.75 | 101.46 | 127.78 | 454.17 | - | - | - |
| Inventory | 88.2M | 40.91M | 35.56M | 32.33M | 46.5M | 17.39M | 15.61M | 9.64M | 7.82M | 1.81M | 1.32M | 0 | 0 | 0 |
| Days Inventory Outstanding | 77.93 | 47.06 | 51.08 | 49.05 | 66.71 | 50.29 | 43.78 | 18.17 | 17.22 | 255.01 | 2.26K | - | - | - |
| Other Current Assets | 19.85M | 3.24M | 27.74M | 93K | 57K | 27K | 60K | 141K | 1.01M | 456K | 304K | 558K | 2.82M | 0 |
| Total Non-Current Assets | 1.48B | 965.42M | 1.18B | 605.71M | 754.14M | 376.53M | 365.95M | 50.58M | 53.73M | 2.08M | 3.44M | 835K | 594K | 773K |
| Property, Plant & Equipment | 15.29M | 16.2M | 20.15M | 22.01M | 26.38M | 27.14M | 27.38M | 20.9M | 9.27M | 1.83M | 1.04M | 738K | 514K | 693K |
| Fixed Asset Turnover | 52.96x | 48.18x | 31.34x | 25.75x | 17.59x | 10.20x | 11.32x | 14.20x | 30.24x | 15.59x | 1.65x | - | - | - |
| Goodwill | 193.88M | 145.93M | 162.33M | 133.86M | 133.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.13B | 669.51M | 891.4M | 421.71M | 567.47M | 268.72M | 335.9M | 29.5M | 44.26M | 0 | 2.1M | 0 | 0 | 0 |
| Long-Term Investments | 1.06M | 1.06M | 0 | 0 | 2.55M | 2.55M | 0 | 0 | 0 | 97K | 97K | 97K | 0 | 0 |
| Other Non-Current Assets | 14.21M | 20.19M | 9.41M | 1.87M | 100K | 87K | 2.67M | 178K | 204K | 161K | 301K | 0 | 80K | 80K |
| Total Assets | 2.1B | 1.66B | 1.66B | 1.14B | 1.17B | 692.08M | 643.84M | 306.3M | 291.25M | 135.57M | 162.02M | 97.72M | 5.09M | 9.03M |
| Asset Turnover | 0.43x | 0.47x | 0.38x | 0.50x | 0.40x | 0.40x | 0.48x | 0.97x | 0.96x | 0.21x | 0.01x | - | - | - |
| Asset Growth % | 65.36% | -0.41% | 45.51% | -2.63% | 69.65% | 7.49% | 110.2% | 5.17% | 114.83% | -16.32% | 65.8% | 1819.8% | -43.66% | - |
| Total Current Liabilities | 603.09M | 440.03M | 509.51M | 457.92M | 433.73M | 279.57M | 239.45M | 201.76M | 187.48M | 31.49M | 22.93M | 5.76M | 10.42M | 2.62M |
| Accounts Payable | 10.43M | 10.66M | 3.93M | 8.69M | 3.49M | 4.19M | 10.02M | 6.25M | 12.15M | 5.68M | 9.11M | 3.54M | 2.21M | 1.22M |
| Days Payables Outstanding | 10.16 | 12.26 | 5.65 | 13.19 | 5.01 | 12.11 | 28.08 | 11.77 | 26.77 | 799.48 | 15.6K | 7.55K | - | - |
| Short-Term Debt | 60.5M | 30.41M | 64.58M | 183.33M | 162.5M | 48.35M | 47.49M | 3.83M | 1.64M | 1.48M | 2.67M | 2.67M | 6.19M | 333K |
| Deferred Revenue (Current) | 3.78M | 667K | 0 | 988K | 0 | 0 | 0 | 0 | 0 | 0 | 4.94M | -9.55M | 0 | 0 |
| Other Current Liabilities | 15.74M | 378.73M | 7.61M | 253.91M | 1.51M | 851K | 1.42M | 5.7M | 167.7M | 18.21M | 4.29M | 661K | 1.38M | 619K |
| Current Ratio | 1.01x | 1.57x | 0.95x | 1.17x | 0.97x | 1.13x | 1.16x | 1.27x | 1.27x | 4.24x | 6.92x | 16.81x | 0.43x | 3.16x |
| Quick Ratio | 0.87x | 1.48x | 0.88x | 1.10x | 0.86x | 1.07x | 1.10x | 1.22x | 1.23x | 4.18x | 6.86x | 16.81x | 0.43x | 3.16x |
| Cash Conversion Cycle | 183.74 | 133.62 | 177.53 | 151.48 | 205.76 | 177.71 | 113.79 | 96.15 | 91.91 | -416.7 | -12.89K | - | - | - |
| Total Non-Current Liabilities | 1.2B | 915.13M | 925.24M | 489.96M | 545.56M | 209.58M | 218.36M | 17.11M | 12.18M | 7.16M | 4.18M | 6.88M | 6.91M | 834K |
| Long-Term Debt | 1.02B | 906.02M | 787.9M | 483.84M | 538.45M | 201.63M | 209.59M | 7.67M | 9.86M | 0 | 1.48M | 4.15M | 6.81M | 640K |
| Capital Lease Obligations | 15.23M | 4.13M | 5.54M | 6.12M | 7.11M | 7.95M | 8.77M | 9.44M | 0 | 0 | 34K | 68K | 101K | 135K |
| Deferred Tax Liabilities | 60.93M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 142.93M | -4.13M | 121.8M | 0 | 0 | 0 | 0 | 0 | 676K | 0 | 0 | 0 | 0 | 59K |
| Total Liabilities | 1.8B | 1.36B | 1.43B | 947.88M | 979.29M | 489.15M | 457.81M | 218.87M | 199.66M | 31.49M | 27.11M | 12.65M | 17.33M | 3.45M |
| Total Debt | 1.09B | 940.56M | 859.3M | 674.28M | 709.17M | 258.75M | 266.58M | 21.59M | 11.5M | 1.48M | 4.15M | 6.81M | 13.01M | 973K |
| Net Debt | 942.21M | 689.46M | 788.73M | 435.34M | 535.49M | 72.32M | 92.47M | -148.43M | -135.13M | -117.22M | -149.08M | -88.88M | 11.37M | -6.58M |
| Debt / Equity | 3.67x | 3.12x | 3.75x | 3.45x | 3.64x | 1.28x | 1.43x | 0.25x | 0.13x | 0.01x | 0.03x | 0.08x | - | 0.17x |
| Debt / EBITDA | 3.60x | 2.28x | 2.53x | 2.13x | 4.12x | 2.99x | 2.26x | - | 0.13x | - | - | - | - | - |
| Net Debt / EBITDA | 3.12x | 1.67x | 2.33x | 1.38x | 3.11x | 0.84x | 0.79x | - | -1.50x | - | - | - | - | - |
| Interest Coverage | 1.26x | 2.13x | 2.33x | 1.91x | 0.54x | 0.84x | 1.95x | -24.00x | -0.94x | - | -1000.87x | -61.08x | -70.10x | -212.12x |
| Total Equity | 296.44M | 301.68M | 228.84M | 195.43M | 194.84M | 202.93M | 186.03M | 87.43M | 91.58M | 104.08M | 134.91M | 85.07M | -12.24M | 5.58M |
| Equity Growth % | 107.29% | 31.83% | 17.1% | 0.3% | -3.98% | 9.08% | 112.77% | -4.53% | -12.01% | -22.85% | 58.58% | 794.98% | -319.29% | - |
| Book Value per Share | 7.58 | 7.60 | 5.66 | 4.68 | 5.76 | 4.94 | 5.29 | 2.61 | 2.78 | 3.44 | 5.56 | 6.28 | -1.64 | 0.75 |
| Total Shareholders' Equity | 296.44M | 301.68M | 228.84M | 195.43M | 194.84M | 202.93M | 186.03M | 87.43M | 91.58M | 104.08M | 134.91M | 85.07M | -12.24M | 5.58M |
| Common Stock | 42K | 41K | 40K | 38K | 37K | 36K | 35K | 34K | 33K | 33K | 29K | 21K | 8K | 1K |
| Retained Earnings | -79.92M | -101.13M | -164M | -233.19M | -281.34M | -256.34M | -333.15M | -359.9M | -337.18M | -298.05M | -223.18M | -129.01M | -101.75M | -80.54M |
| Treasury Stock | -262.51M | -222.51M | -197.5M | -137.38M | -61.92M | -42.86M | 0 | 0 | 0 | 0 | 0 | -3K | -3K | -3K |
| Accumulated OCI | 0 | 319K | 55K | 14K | 0 | 0 | 0 | 0 | 0 | -1.67M | -1.33M | -1.07M | -903K | -716K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying COLL stock.
As of 2025, Collegium Pharmaceutical, Inc. (COLL) had total assets of $1.66B including $691.4M in current assets.
Collegium Pharmaceutical, Inc. (COLL) carries total debt of $940.6M, offset by $406.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Collegium Pharmaceutical, Inc. (COLL) has total shareholders' equity (book value) of $301.7M ($7.60 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Collegium Pharmaceutical, Inc. (COLL) reported a current ratio of 1.57x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Leverage limits shortfall tolerance
Metrics are mathematically derived from official filings.
Equity Rebuilding Lags Rising Liabilities
Based on reported figures, COLL's equity rose from $216.6M in 2024Q2 to $296.4M in 2026Q3, while total liabilities climbed to $1.8B, so the balance sheet is strengthening in absolute terms but still carries leverage that grew faster than capital.
The equity build is largely the product of retained earnings moving from deeply negative territory toward -$79.9M, which suggests the accumulated deficit is narrowing but not yet reversed. Total assets expanded by roughly $1.0B over the period, driven mainly by acquired goodwill and intangibles, indicating that the asset base reflects purchased rather than organically built value. Investors should monitor whether earnings retention can keep pace with liability growth, since the current trajectory appears dependent on acquisition financing.
Elevated Leverage Persists Despite Deleveraging Attempts
As reported in financial statements, COLL's debt-to-equity ratio stood at 3.12 in 2025Q4 and 3.67 in 2026Q3, with total debt near $1.1B against equity of roughly $296M, indicating leverage that remains structurally high.
Debt rose from about $559M in 2024Q2 to roughly $1.1B in 2026Q3, and the 2026Q2 figure of $857.8M followed by a 2026Q3 reading of $1.1B suggests new borrowing rather than repayment. The leverage appears acquisition-driven instead of operationally necessitated, which may indicate a deliberate portfolio expansion strategy. Refinancing exposure and the cost of servicing this debt warrant further investigation, particularly given the narrow net margin of 8.1%.
Thin Liquidity Buffer Against Shocks
Based on reported figures, COLL's current ratio fell to 1.01 in 2026Q3 from 1.71 in 2026Q1, while cash of $144.8M sits against roughly $1.1B of debt, leaving a limited buffer relative to obligations.
The current ratio decline across recent quarters suggests short-term obligations are growing faster than liquid resources, despite cash rebounding from $39.0M in 2024Q3. Cash coverage of total debt is modest, which may constrain flexibility if revenue growth stalls or regulatory pressures intensify. This appears to make the company more dependent on continued operating cash generation than on balance sheet reserves.
Goodwill-Heavy Asset Base Limits Tangible Backing
According to reported balance sheet data, COLL's goodwill of $193.9M and net PP&E of only $15.3M indicate that the asset base is dominated by acquired intangibles and intangible-linked value rather than physical productive capacity.
The minimal PP&E relative to total assets of $2.1B is consistent with an asset-light specialty pharma model, where value resides in product rights and label exclusivity. The reliance on acquired intangibles means impairment risk is a material consideration if portfolio economics deteriorate. Tangible equity is negative once intangibles are excluded, which suggests creditor protection depends on the continued cash flow of the acquired franchises.
Deferred Revenue Offers Limited Forward Signal
Based on reported figures, COLL's deferred revenue fell from $20.0M in 2025Q1 to $10.4M in 2026Q3, with a 2026Q1 reading of only $667K, providing little evidence of a growing contracted revenue backlog.
The decline in deferred revenue suggests reduced advance billing or prepayment activity, which may indicate that near-term revenue visibility rests mainly on prescription run-rates rather than contracted commitments. The volatility of this line, including the near-zero 2026Q1 figure, makes it an unreliable forward indicator on its own. Investors may need to rely on prescription trends and guidance commentary to assess forward revenue durability.
Cash Generation Masks Leverage Exposure
Based on reported figures, COLL's cumulative operating cash flow of roughly $636M over ten quarters appears strong, yet a debt-to-equity ratio of 3.12 suggests that cash generation may overstate true financial flexibility.
Operating cash flow substantially exceeds reported net income, which points to heavy non-cash amortization and may make the operating picture look healthier than the balance sheet supports. Much of the cash generated appears directed toward acquisitions rather than debt reduction, so headline cash strength may not translate into balance sheet resilience. If revenue growth stalls further, the combination of high leverage and acquisition-dependent growth may limit management's options.